Nanodiamonds conjugated upconversion nanoparticles for bio-imaging and drug delivery

J Colloid Interface Sci. 2019 Mar 1:537:316-324. doi: 10.1016/j.jcis.2018.11.028. Epub 2018 Nov 10.

Abstract

A multifunctional nanoplatform with simultaneous imaging and therapeutic capacities has been fabricated by covalently conjugating nanodiamonds (NDs) with upconversion NaYF4:Yb,Er nanoparticles (UCNPs). Green emission can be observed for the UCNP-NDs composites under 980 nm excitation, and in vitro imaging was carried out towards HeLa cells. The UCNP-NDs also shows good drug storage capability toward anticancer drug doxorubicin (Dox) and exhibits significant pH-dependent drug-release behavior. Dox-loaded UCNP-NDs shows higher therapy efficiency towards Hela cells than free Dox when the equivalent concentration of the Dox is more than 10 μg/mL. Thus, a favorable strategy may be provided to decrease the side effects of Dox, minimize drug dose, and improve its efficacy. These findings highlight the fascinating features of UCNP-NDs nanocomposites as upconversion fluorescence imaging contrast agents and doxorubicin loading carrier. In addition, this work may also provide a novel strategy for the design of multifunctional nanoplatforms.

Keywords: Cell imaging; Drug delivery; Nanodiamonds; Upconversion nanoparticles.

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Cell Proliferation / drug effects
  • Contrast Media / chemistry
  • Dose-Response Relationship, Drug
  • Doxorubicin / administration & dosage*
  • Doxorubicin / chemistry
  • Doxorubicin / pharmacology
  • Drug Delivery Systems*
  • Drug Screening Assays, Antitumor
  • Female
  • HeLa Cells
  • Humans
  • Nanoparticles / chemistry*
  • Optical Imaging*
  • Particle Size
  • Structure-Activity Relationship
  • Surface Properties
  • Uterine Cervical Neoplasms / diagnostic imaging*
  • Uterine Cervical Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Contrast Media
  • Doxorubicin